Metastasis-Directed Therapy Protective in Recurrent Prostate Cancer
New findings could have implications for the use of salvage therapies.
New findings could have implications for the use of salvage therapies.
The median survival for patients with metastatic bladder cancer is increasing, possibly due to increasing use of immunotherapy.
Investigators analyzed data from 3 randomized controlled trials and data from their own prospective institutional database.
Patients undergoing radical cystectomy for bladder cancer have an increased risk of thromboembolic events that may persist for months after surgery.
Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Investigators performed a subgroup analysis of the phase 3 ARASENS trial.
Grade 2 or higher gastrointestinal toxicities after hypofractionated prostate cancer radiation therapy occurred in a significantly lower proportion of men who received a hyaluronic acid spacer compared with those who did not.
Investigators estimated prevalence based on the number of de novo and recurrent cases of metastatic prostate cancer.
Phosphodiesterase-5 inhibitor use after robotic prostate cancer surgery was associated with a 57% lower risk of death.
Percutaneous cryoablation for cT1b renal tumors is associated with a higher rate of local disease recurrence compared with partial nephrectomy, new data suggest.